


PLATELET INTERACTIONS WITH LEUKOCYTES AND ENDOTHELIAL CELLS IN VASCULAR INFLAMMATION

DIMITRIOS A. STAKOS, FESC
ASSIST. PROFESSOR OF CARDIOLOGY
ALEXANDROUPOLIS, GREECE
www.Cardioalex.gr



Platelets and the endothelium


10,000 trips around the circulatory loop during their week lifetime

Homotypic and heterotypic interactions


By paracrine signaling

via transient interactions (“give-and-go” mechanism),
or through receptor-mediated cell–cell adhesion.


However, most PLTs never undergo firm adhesion to the endothelium



Platelet adhesion to ECM after denudation




Sub-endothelial layers are exposed



Rolling at high shear






Collagen / vW / vitronectin/ laminin, fibronectin




Collagen / α W / vitronectin/ laminin, fibronectin



Collagen / vW / vitronectin/ laminin, fibronectin



Collagen / vW / vitronectin/ laminin, fibronectin



Collagen / vW / vitronectin/ laminin, fibronectin




Collagen / vW / vitronectin/ laminin / fibronectin



Collagen / vW / vitronectin/ laminin / fibronectin

Initial Adhesion / Rolling at High Shear



GP Ib/V/IX

Glycocalyx

GP IIb/IIIa



INITIAL PLT RICH
THROMBUS


Iib/IIIa (act)

PLT-PLT interactions

Fibrinogen

Firm adhesion

vWF




.. not really a PLT – EC interaction

Platelet adhesion to “intact” endothelium

IN VITRO STUDIES (static conditions)

Activated PLT



- vWF
- ADP
- TF
- $\beta 1$ integrins
- E-selectin
- P-selectin
- VCAM1

GP Ib/IV/IX

vW

Fg



Fbn

ICAM-1

$\alpha v \beta 3$



ACTIVATED HUVECs

1. PLTs adhere to sbECM
2. PLTs form aggregates
3. PLTs adhere to activated endothelium in vitro, but also..




1. PLTs adhere to sbECM
2. PLTs form aggregates
3. PLTs adhere to activated endothelium in vitro, but also..
4. PLTs adhere to endothelium under flow

(a. tethering b. rolling c. firm adhesion)



1. PLTs adhere to sbECM
2. PLTs form aggregates
3. PLTs adhere to activated endothelium in vitro
4. PLTs adhere to endothelium under flow

(a. tethering b. rolling c. firm adhesion)




Selectins







Integrins



P-selectin (CD62P) and E-selectin expression in inflamed endothelium



P-selectin expression in mouse inflamed endothelium (Isc/Repf)



Arteriole




Venule

Control


I/R injury

fluorescence microscopy (PLT – EC interactions 5 min after reperfusion)


Rhodamine-6G-labeled platelets



Control animals





I/R 5 minutes after reoxygenation




Not only at small arterioles..

Platelets adhere at lesion-prone sites before the development of atherosclerotic plaque



Requirements for these interactions


- Non activated PLT – non activated EC
- Non activated PLT – activated EC
- Activated PLT – non activated EC
- Activated PLT – activated EC




We know that activated ECs express P-selectin.

How do PLTs roll on activated ECs ? (P-selectin ligands)


GPIb/IX/V complex as PLT ligand to EC P-selectin




P selectin glycoprotein ligand1 (PSGL-1) as PLT ligand to EC P-selectin




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




P selectin – PSGL-1 or GPIIb/IX/V ligation insufficient for stable adhesion




Initial attachment (rolling)




Initial attachment (rolling)





Initial attachment (rolling)




Integrin activation









P selectin





P selectin





P selectin







PLT contact with endothelium activates ECs

How do Platelets activate Endothelial Cells ?


Activated platelets mediate inflammatory signaling by IL-1 synthesis




Platelet derived IL-1 stimulates secretion of IL-6 by cultured endothelial cells




IL-1 mediated ICAM-1 expression by endothelial cells




IL-1 mediated MCP-1 expression by endothelial cells followed by ...



IL-1 β induced Neutrophil adhesion to endothelial cells




NF κ B dependent chemokine secretion by ECs




Endothelial activation after PLT – EC interaction (CD40 – CD40L)

CD40L induces the expression of adhesion molecules, cytokines and chemo-attractants, proteases and tissue factor by ligating CD40 on endothelial cells and monocytes.


*uPA, tPA, MMP-1, MMP-2, MMP-9 and ROS-
EC proteolytic activity and local inflammation





How does this work..




Cd40L released within seconds after GPIIb/IIIa ligation (sCD40L released within minutes to hours)



Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with ACS




Chemokines involved in PLT – EC - Leukocyte interactions



Chemokine (C-C motif) ligand 5 (also CCL5) also known as RANTES*


recruits leukocytes into inflammatory sites

(*Regulated upon Activation, Normal T-cell Expressed, and Secreted)
C: Cystin




RANTES deposition on ECs requires previous PLT adhesion via P-selectin

RANTES deposition



Chemokines involved in PLT – EC - Leukocyte interactions




Chemokine (CXC motif) ligand 4 (also CXCL4) it is also known as **PF4***


chemotactic and differentiating factor for neutrophils and monocytes

(*Platelet Factor 4)

PF4 induces morphological alterations to monocytes




Treated with PF4




Untreated Monocytes

PF4 induces TNF- α release from monocytes



PF4 promotes differentiation of monocytes into macrophages and inhibit their apoptosis

No PF4




Necrotic cells

Unstimulated monocytes rapidly undergo apoptosis



Apoptotic cells

Fluorescence intensity of PI



Necrotic cells


Apoptotic cells

PF4

PF4 interferes with LDL endocytosis





A key point of how PLTs promote atherogenesis in its initial steps

PF4 inhibits LDL-R dependent binding and internalization of LDL cholesterol by vascular cells






LDL in coated pits



LDL – LDLR clusters in cell surface in the presence of PF4





PF4 stimulates binding of ox-LDL to ECs and macrophages











LDL-LDLR complex
Retention on cell surface




Increased residence time in the vasculature
→ oxidative modification of LDL


Co-localization of PF4 and ox-LDL in human atherosclerotic vessels




PF4-mediated monocyte recruitment ...




PF4 enhanced the arrest of RANTES-stimulated monocytes on activated ECs under flow




...and differentiation into macrophages




PF4 enhances binding of oxLDL from macrophages




PF4 enhances binding of oxLDL from macrophages




Binding of PF4 to the monocyte surface was increased in the presence of RANTES





PF4 enhances binding and endocytosis of oxLDL from macrophages




Subsequent esterification of ox-LDL in macrophages accelerating the formation of foam cells.






Very early development of atherosclerosis in a nonhuman primate beneath an intact endothelium.




What we have seen until now..

Platelet interaction with endothelium and at site recruitment of WBCs may initiate atherosclerosis




Platelet-leukocyte interactions

Platelet – leukocyte interactions at site






Platelet – leukocyte interactions in circulation


(turbulent flow, cytokines, inflammatory conditions, AMI, after rolling in activated Ecs)




Platelet – Leukocyte Aggregates




PLT – Leukocyte initial tethering




PSGL-1 ligation prepare rolling through actin cytoskeleton




PLT – Leukocyte firm adhesion



PLT – Leukocyte firm adhesion




Platelet mediated leukocyte activation




IL-1, IL-8, MCP-1, TNF-α, MMPs

May A, ATVB, 2008
Conde I, ATVB, 2005


CD11b/CD18 up-regulation and CD62L shedding after endothelial injury in humans




PLT – Leukocyte aggregates (beautiful images! – any clinical importance?)





Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin. Diagnostic tool?




Higher prevalence of PLT-Monoc aggregates in AMI are reduced after successful revascularization A prognostic marker?




Leuk – PLT Aggregates as markers of CVD in diabetes. Risk stratification?



Phagocytic clearance of activated platelets by leukocytes (markers)..



Strike PC, PNAS, 2005



Maugeri N, Blood, 2011


...or active players?

PMA have ... compared to PLT-free monocytes

Increased primary (Leuk-EC) and secondary (Leuk-Leuk) tethering

Increased integrin expression and activity

Increased transmigration




PMA have ... compared to PLT-free monocytes


Increased primary (Leuk-EC) and secondary (Leuk-Leuk) tethering

Increased integrin expression and activity

Increased transmigration



Contribute to (PMA mediated) PLT deposition




The Neutrophil Extracellular Traps (NETs)


NETs are extracellular DNA fibers (taken out of the cell) and neutrophil antimicrobial proteins after Neutrophil suicide in tissues or blood stream

Neutrophil Extracellular Traps (NET) interactions with Platelets


Neutrophil treated with anti-Fas antibodies



apoptotic morphology




Nuclear alterations




mixing of nuclear, cytoplasmic,
and granular components

cell death and NET formation


Neutrophil Extracellular Traps (NET) interactions



Neutrophil Extracellular Traps (NET) - Platelet immobilization – activation – thrombus?



PLTs captured green





Cause or effect ?



NETs are present in red thrombi together with RBCs

Platelet and endothelial progenitor cells


Platelet recruit endothelial progenitor cells at sites of vascular injury



Platelet recruit endothelial progenitor cells at sites of vascular injury via SDF-1




Platelet and endothelial progenitor cells Two different ways of differentiation



Daub K, FASEB, 2006
Langer H, Circ Res, 2006


PLTs + EPCs → CD68+ (foam cells)

PLTs + EPCs → Ecs (repair)



Conclusions

Platelet adhesion to Endothelium → Promotes Cell “Inter-activation”





Adhesion molecules
Cytokines
Chemoattractants
Cell interactions

Can these data be transferred to human situation?

If platelets initiate atherosclerosis...

Will long-term antiplatelet / anti-inflammatory therapy be used as primary prevention at early stages of atherosclerosis, at least in high risk individuals ?

Clinical implications




Fewer macrophages more collagen more stable

Rat-IgG

Saline

α -CD40L





SMC

MØ

Collagen

■ BE

% sCD40L release



Since atherosclerosis involves ECs, leukocytes, PLTs and their interactions, then targeting all players simultaneously may be more effective than only one (platelets) as we do now

If indeed platelets are inflammatory cells, then targeting their pro-inflammatory activity rather than PLT aggregation will be an attractive alternative area of research for limiting CVD

Thank you for your attention